Condition
Stereotactic Radiotherapy
Total Trials
4
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06822491Active Not Recruiting
Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response
NCT06457906Phase 3Recruiting
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
NCT06231186Not ApplicableRecruiting
a Feasibility Study of iHD-SRT for BM
NCT06165900Phase 2RecruitingPrimary
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
Showing all 4 trials